Debiopharm and NanoCarrier Sign License and Supply Agreement for Dach-Platin Polymeric Micelle i... (atin but by using micellarnanoparticles ...)

Debiopharm and NanoCarrier Sign License and Supply Agreement for Dach-Platin Polymeric Micelle in Oncology

Date:10/31/2007

atin, but by using micellar nanoparticles, we believe we can develop a new, more effective DACH-platin anticancer drug with possible lower side effects.

The basic technology of this formulation was invented by Professor Kataoka of the University of Tokyo. The technology was licensed in from TOUDAI TLO Ltd. The basic Japanese patent for DACH-platin micelle has been granted as Patent No. 39955992 in May 2007.

About Debiopharm Group

Debiopharm Group is a global biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates. Debiopharm develops its products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marketing.

Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed three products: Eloxatin(R), Decapeptyl(R) and Trelstar(R) with global combined sales in excess of $2.6 billion in 2006.

For more information on Debiopharm Group, please visit: http://www.debiopharm.com.

About NanoCarrier Co., Ltd.

NanoCarrier is a biotech that focuses on the research and development of drugs primarily in the field of cancer with micellar nanoparticles technology. Micellar nanoparticles (also known as polymeric micelle) are formed from biocompatible block copolymers which consist of a hydrophilic polymer, polyethyleneglycol (PEG), and a hydrophobic polymer, polyamino acid derivative.

By encapsulating drugs efficiently inside, micellar nanoparticles work as functional particles that stay in bloodstream for a long period of time and deliver drugs preferentially to targeted sites, thus minimizing unfavourable side effects and impro
'/>"/>

1

GOOD

Page: 1 2 3
Related medicine news :

1. Ranbaxy to Market Debiopharms New Drug in India
2. Georgia: Indian doctors license cancelled
3. US Government Licenses New Hypertension Drug
4. Proposal to license Ayurveda Practitioners in the US
5. Genomatix Licensed By Bayer Healthcare
6. Panacea Biotec In-Licenses FMD Vaccine
7. Test for Esophageal Reflux Licensed to Bayer by University
8. Thailand Goes Ahead With Licenses for Generic Drugs
9. Swedish Biotech Licenses HIV Drug to China for Development
10. More Foreign Trained Doctors Receive Licenses
11. FDA Licenses First US Vaccine Against Avian Flu

Post Your Comments:

Debiopharm and NanoCarrier Sign License and Supply Agreement for Dach-Platin Polymeric Micelle i...(atin but by using micellarnanoparticles ...),Health